1. Scrip
  2. >>Business

Several Options Remain For Cidara’s Flu Candidate After J&J Halts Development

 
• By Ayisha Sharma

Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.  

hands holding up a paper cut-out showing arrows in different directions
Janssen Could Out-License The Asset Or Return It To Cidara • Source: Shutterstock
Key Takeaways:

  • Janssen has hit pause on mots of its infectious disease programs amidst a strategic change.

  • CD388 has shown early promise in preventing influenza in an ongoing Phase IIa trial.

  • The asset is likely to be developed further by another pharma company or Cidara itself.

Janssen Pharmaceuticals Inc. has hit the brakes on the development of partner Cidara Therapeutics, Inc

The discontinuation is part of Janssen’s shift away from infectious diseases R&D amid a broader restructuring of its business and does not seem related to CD388’s clinical performance or potential

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.